
    
      Approximately 48 subjects will be enrolled to receive orally administered KD025 200 mg QD
      (once daily), KD025 200 mg BID (twice daily), or KD025 400 mg QD. Once a recommended dose is
      chosen, approximately 40 additional subjects will be enrolled into the study at that dose.

      Study drug will be administered in 28-day cycles until disease progression or unacceptable
      toxicity. Subjects may receive study drug in the inpatient or outpatient setting.
    
  